The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 230-234

  Salkeld, Erin ^a   Ferris, Lorraine E ^a,b   Juurlink, David N ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PLACENTAL DELIVERY; POSTPARTUM HEMORRHAGE; PRENATAL PERIOD; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; THIRD TRIMESTER PREGNANCY; THROMBOCYTE AGGREGATION;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CLINICAL PHARMACY INFORMATION SYSTEMS; DELIVERY, OBSTETRIC; DRUG UTILIZATION REVIEW; FEMALE; GESTATIONAL AGE; HUMANS; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; OBSTETRIC LABOR COMPLICATIONS; ONTARIO; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, MULTIPLE; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 40949144117     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318166c52e     Document Type: Article

References (39)

1. Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health. 2003;12:373-380.
2. Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol. 1989;57:269-274.
3. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698-709.
4. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398-407.
5. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60:659-666.
6. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol. 2003;59:127-133.
7. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326:1014-1017.
8. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85-102.
9. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587.
10. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? Can Med Assoc J. 2005;172:1457-1459.
11. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-408.
12. Dalton SO, Sørenson HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs. 2006;20:143-151.
13. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:1-6.
14. de Abajo FJ, Montero D, Rodŕguez LAG, et al. Antidepressants and the risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006;98:304-310.
15. Layton D, Clark DWJ, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Eur J Clin Pharmacol. 2001;57:167-176.
16. Meijer WEE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367-2370.
17. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119-128.
18. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000;68:435-442.
19. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12-16.
20. Lee A, Leong M, Aiello J, et al. Poor neonatal adaptation following third trimester paroxetine exposure [abstract]. Can J Clin Pharmacol. 2003;10:151.
21. Combs CA, Murphy EL, Laros RK. Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol. 1991;77:69-76.
22. Combs CA, Murphy EL, Laros RK. Factors associated with hemorrhage in cesarean deliveries. Obstet Gynecol. 1991;77:77-82.
23. Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc. 2004;52:794-798.
24. Juurlink DN, Mamdani MM, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc. 2003;289:1652-1658.
25. Mamdani MM, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363;1751-1756.
26. Levy AR, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71.
27. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
28. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405-1410.
29. Mamdani MM, Tu K, van Walraven C, et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ. 2000;162:1421-1424.
30. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
31. Allison PD. Logistic Regression Using the SAS System. Carey, NC: SAS Institute; 1999.
32. Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Toronto, ON: Institute for Clinical Evaluative Sciences; 2006.
33. Romano PS, Yasmeen S, Schembri ME, et al. Coding of perineal lacerations and other complications of obstetric care in hospital discharge data. Obstet Gynecol. 2005;106:717-725.
34. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother. 1992;26:1517-1519.
35. Bak S, Tsiropoulos I, Kjærsgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33:1465-1473.
36. de Abajo FJ, Rodríguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-1109.
37. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am. 2003;26:547-562.
38. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005;28:565-581.
39. Ward RM, Bates BA, McCarver DG, et al. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105:880-887.